AIMS/HYPOTHESIS: The contribution of immune cells to the inflammasome that characterises type 2 diabetes mellitus and obesity is under intense research scrutiny. We hypothesised that early changes in glucose metabolism following gastric banding surgery may relate to systemic inflammation, particularly cell-mediated immunity. METHODS: Obese participants (BMI 43.4 ± 4.9 kg/m(2), n = 15) with diabetes or impaired glucose tolerance (IGT) underwent laparoscopic adjustable gastric banding surgery. Measurements taken before, and at 2 and 12 weeks after surgery included: fasting glucose, glucose levels 2 h after a 75 g oral load, glucose incremental AUC, oral glucose insulin sensitivity index (OGIS), circulating immune cell numbers and activation, and adipokine levels. Subcutaneous and visceral adipose tissue were collected at surgery, and macrophage number and activation measured. RESULTS: There were significant reductions in fasting and 2 h glucose, as well as improved OGIS at 2 and 12 weeks. At 12 weeks, 80% of the diabetic participants reverted to normal glucose tolerance or IGT, and all IGT participants had normalised glucose tolerance. The 12 week fall in fasting glucose was significantly related to baseline lymphocyte and T lymphocyte numbers, and to granulocyte activation, but also to the magnitude of the 12 week reduction in lymphocyte and T lymphocyte numbers and TNF-α levels. In a model that explained 75% of the variance in the change in fasting glucose, the 12 week change in T lymphocytes was independently associated with the 12 week fall in fasting glucose. CONCLUSIONS/ INTERPRETATION: Rapid improvements in glucose metabolism after gastric banding surgery are related to reductions in circulating pro-inflammatory immune cells, specifically T lymphocytes. The contribution of immune cell-mediated inflammation to glucose homeostasis in type 2 diabetes and its improvement after bariatric surgery require further investigation.
AIMS/HYPOTHESIS: The contribution of immune cells to the inflammasome that characterises type 2 diabetes mellitus and obesity is under intense research scrutiny. We hypothesised that early changes in glucose metabolism following gastric banding surgery may relate to systemic inflammation, particularly cell-mediated immunity. METHODS: Obese participants (BMI 43.4 ± 4.9 kg/m(2), n = 15) with diabetes or impaired glucose tolerance (IGT) underwent laparoscopic adjustable gastric banding surgery. Measurements taken before, and at 2 and 12 weeks after surgery included: fasting glucose, glucose levels 2 h after a 75 g oral load, glucose incremental AUC, oral glucose insulin sensitivity index (OGIS), circulating immune cell numbers and activation, and adipokine levels. Subcutaneous and visceral adipose tissue were collected at surgery, and macrophage number and activation measured. RESULTS: There were significant reductions in fasting and 2 h glucose, as well as improved OGIS at 2 and 12 weeks. At 12 weeks, 80% of the diabeticparticipants reverted to normal glucose tolerance or IGT, and all IGT participants had normalised glucose tolerance. The 12 week fall in fasting glucose was significantly related to baseline lymphocyte and T lymphocyte numbers, and to granulocyte activation, but also to the magnitude of the 12 week reduction in lymphocyte and T lymphocyte numbers and TNF-α levels. In a model that explained 75% of the variance in the change in fasting glucose, the 12 week change in T lymphocytes was independently associated with the 12 week fall in fasting glucose. CONCLUSIONS/ INTERPRETATION: Rapid improvements in glucose metabolism after gastric banding surgery are related to reductions in circulating pro-inflammatory immune cells, specifically T lymphocytes. The contribution of immune cell-mediated inflammation to glucose homeostasis in type 2 diabetes and its improvement after bariatric surgery require further investigation.
Authors: Daniel B Leslie; Robert B Dorman; Federico J Serrot; Therese W Swan; Todd A Kellogg; Gonzalo Torres-Villalobos; Henry Buchwald; Bridget M Slusarek; Barbara K Sampson; John P Bantle; Sayeed Ikramuddin Journal: Obes Surg Date: 2012-03 Impact factor: 4.129
Authors: Stacy A Brethauer; Helen M Heneghan; Shai Eldar; Patrick Gatmaitan; Hazel Huang; Sangeeta Kashyap; Heather L Gornik; John P Kirwan; Philip R Schauer Journal: Surg Endosc Date: 2011-03-17 Impact factor: 4.584
Authors: Ted D Adams; Lance E Davidson; Sheldon E Litwin; Ronette L Kolotkin; Michael J LaMonte; Robert C Pendleton; Michael B Strong; Russell Vinik; Nathan A Wanner; Paul N Hopkins; Richard E Gress; James M Walker; Tom V Cloward; R Tom Nuttall; Ahmad Hammoud; Jessica L J Greenwood; Ross D Crosby; Rodrick McKinlay; Steven C Simper; Sherman C Smith; Steven C Hunt Journal: JAMA Date: 2012-09-19 Impact factor: 56.272
Authors: James M Isbell; Robyn A Tamboli; Erik N Hansen; Jabbar Saliba; Julia P Dunn; Sharon E Phillips; Pamela A Marks-Shulman; Naji N Abumrad Journal: Diabetes Care Date: 2010-04-05 Impact factor: 19.112
Authors: Ulrich Kintscher; Martin Hartge; Katharina Hess; Anna Foryst-Ludwig; Markus Clemenz; Martin Wabitsch; Pamela Fischer-Posovszky; Thomas F E Barth; Duska Dragun; Thomas Skurk; Hans Hauner; Matthias Blüher; Thomas Unger; Anna-Maria Wolf; Uwe Knippschild; Vinzenz Hombach; Nikolaus Marx Journal: Arterioscler Thromb Vasc Biol Date: 2008-04-17 Impact factor: 8.311
Authors: Marlena M Holter; Roxanne Dutia; Sarah M Stano; Ronald L Prigeon; Peter Homel; James J McGinty; Scott J Belsley; Christine J Ren; Daniel Rosen; Blandine Laferrère Journal: Diabetes Care Date: 2016-11-08 Impact factor: 19.112
Authors: J R Villarreal-Calderón; E C Castillo; R X Cuellar-Tamez; M García-Garza; L Elizondo-Montemayor; G García-Rivas Journal: J Endocrinol Invest Date: 2021-05-15 Impact factor: 4.256
Authors: Nels C Olson; Margaret F Doyle; Ian H de Boer; Sally A Huber; Nancy Swords Jenny; Richard A Kronmal; Bruce M Psaty; Russell P Tracy Journal: PLoS One Date: 2015-10-12 Impact factor: 3.240
Authors: John Edward Farey; Oliver M Fisher; Angelique J Levert-Mignon; Patrice M Forner; Reginald V Lord Journal: Obes Surg Date: 2017-03 Impact factor: 4.129